Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C DelbaldoAERO, GERCOR, FNLCC and FFCD

Abstract

The R98 trial explores the addition of irinotecan to a 5-fluorouracil (5-FU) plus leucovorin (5-FU/LV) adjuvant regimen in optimally resected stages II-III rectal cancers. We report the updated long-term results. Disease-free survival (DFS) was the primary end point. Between March 1999 and December 2005, 357 patients were randomized: 178 in 5-FU/LV and 179 in LV5-FU2 + irinotecan arm. The trial was stratified by control arm: Mayo Clinic regimen or LV5-FU2 regimen. Three hundred and fifty-seven randomized patients were evaluable for efficacy. With a follow-up of 156 months, the DFS was in favour of experimental arm but did not reach statistical significance [hazard ratio (HR) = 0.80, P = 0.154]. The same was observed for overall survival (OS) (HR = 0.87, P = 0.433). The 5-year DFS was 58% in the control arm and 63% in the experimental arm. The 5-year OS was 74% in the control arm and 75% in the experimental arm. Patients allocated to the experimental arm had more grade 3-4 neutropenia when compared with the LV5-FU2 arm (33% versus 6%, P = 0.03), but not when compared with the Mayo Clinic arm (33% versus 36%, P = 0.84). Grade 3-4 diarrhoea tended to be higher in the experimental arm, but analyses stratified by control arm or by r...Continue Reading

References

Mar 14, 1991·The New England Journal of Medicine·J E KrookJ A Mailliard
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Sep 8, 2001·The New England Journal of Medicine·E KapiteijnUNKNOWN Dutch Colorectal Cancer Group
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndreAimery de Gramont
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junichi SakamotoUNKNOWN Meta-Analysis Group in Cancer
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Feb 19, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Boyle, J Ferlay
Mar 1, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J KerrD Hölzel
Sep 15, 2006·The New England Journal of Medicine·Jean-François BossetUNKNOWN EORTC Radiotherapy Group Trial 22921
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardLaurent Bedenne
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J SargentUNKNOWN ACCENT Group
Oct 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence ColletteUNKNOWN European Organisation for Research and Treatment of Cancer Radiation Oncology Group
Jan 31, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M YchouA Kramar
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemDavid Cunningham
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thierry AndréAimery de Gramont
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jun 9, 2010·The Cancer Journal·Benoît RousseauUNKNOWN GERCOR (French Oncology Research Group)
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerHans-Joachim Schmoll
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Greg YothersNorman Wolmark
Mar 17, 2012·Therapeutic Advances in Medical Oncology·Benoist ChibaudelAimery de Gramont

❮ Previous
Next ❯

Citations

Apr 18, 2019·Current Opinion in Oncology·Francesco Sclafani, Alain Hendlisz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.